Literature DB >> 1659748

Delayed elimination of enoxaparin in patients with chronic renal insufficiency.

Y Cadroy1, J Pourrat, M F Baladre, S Saivin, G Houin, J L Montastruc, I Vernier, B Boneu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1659748     DOI： 10.1016/0049-3848(91)90141-i

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  13 in total

Review 1.  Chronic kidney disease in acute coronary syndromes.

Authors:  Giancarlo Marenzi; Angelo Cabiati; Emilio Assanelli
Journal:  World J Nephrol       Date:  2012-10-06

Review 2.  How to balance risks and benefits in the management of CKD patients with coronary artery disease.

Authors:  Giancarlo Marenzi; Nicola Cosentino; Carlo Guastoni
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 3.  Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

Authors:  B S Smith; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 4.  Safety profile of different low-molecular weight heparins used at therapeutic dose.

Authors:  Isabelle Gouin-Thibault; Eric Pautas; Virginie Siguret
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.

Authors:  Philippe Cestac; Haleh Bagheri; Maryse Lapeyre-Mestre; Pierre Sié; Atoussa Fouladi; Eric Maupas; Philippe Léger; Bernard Fontan; Patrice Massip; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Dosing of Enoxaparin in Renal Impairment.

Authors:  Suhail A Shaikh; Randolph E Regal
Journal:  P T       Date:  2017-04

7.  Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.

Authors:  B Green; M Greenwood; D Saltissi; J Westhuyzen; L Kluver; J Rowell; J Atherton
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

9.  Role of Special Coagulation Studies for Preoperative Screening of Thrombotic Complications in Simultaneous Pancreas-Kidney Transplantation.

Authors:  Abdul Moiz; Tariq Javed; Humberto Bohorquez; David S Bruce; Ian C Carmody; Ari J Cohen; Catherine Staffeld-Coit; Qingyang Luo; George E Loss; Jorge Garces
Journal:  Ochsner J       Date:  2015

Review 10.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.